Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 9/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129006 | 0.95 | S1PR1 (0.39) | S1PR1ARPRMT1CARM1PRMT6 | |
| SCHEMBL16129025 | 0.91 | PDE3B (0.41) | S1PR1PRMT1CARM1PRMT6PRMT8 | |
| SCHEMBL16128987 | 0.89 | S1PR1 (0.38) | S1PR1PRMT1CARM1PRMT6PRMT8 | |
| SCHEMBL16129020 | 0.88 | S1PR1 (0.34) | S1PR1ARPRMT1CARM1 | |
| SCHEMBL19904785 | 0.87 | AR (0.33) | S1PR1ARPRMT1CARM1 | |
| SCHEMBL16129018 | 0.87 | CARM1 (0.35) | S1PR1ARPRMT1CARM1PRMT6 | |
| SCHEMBL16128988 | 0.87 | XDH (0.44) | S1PR1PRMT1CARM1PRMT6PRMT8 | |
| SCHEMBL16128994 | 0.86 | AR (0.39) | S1PR1ARPRMT1PRMT6PDE3B | |
| SCHEMBL19431995 | 0.86 | PRMT1 (0.32) | ARPRMT1CARM1PRMT6PRMT8 | |
| SCHEMBL19432090 | 0.84 | S1PR1 (0.34) | S1PR1ARPRMT1CARM1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970134-B1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160039767-A1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| US-8952026-B2 | PRMT1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039767-A1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | S1PR1 2250/4885AR 3500/4885PRMT1 1/4885 |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT6 | S1PR1 1979/4885AR 3426/4885PRMT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.